Skip to main content

Table 2 Known groups’ validity for FACT-8D and EQ-5D-5L Index scores, using baseline data

From: Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

 

FACT-8D

EQ-5D-5L crosswalk

EQ-5D-5L EVS

Mean (SD)

P value

Mean (SD)

P value

Mean (SD)

P value

Baseline lymphoma symptoms

 

0.02

 

< .0001

 

< .0001

 No (N = 117)

0.69 (0.18)

 

0.81 (0.21)

 

0.87 (0.16)

 

 Yes (N = 133)

0.63 (0.28)

 

0.67 (0.22)

 

0.75 (0.21)

 

Presence lymphoma B symptomsa

 

< 0.01

 

< 0.001

 

< 0.001

 No symptoms (N = 186)

0.68 (0.20)

 

0.77 (0.20)

 

0.84 (0.16)

 

 One or more symptoms present (N = 64)

0.60 (0.32)

 

0.63 (0.28)

 

0.71 (0.26)

 

Other MCL-related symptoms

 

0.10

 

<.0001

 

< .0001

 No (N = 140)

0.67 (0.22)

 

0.79 (0.21)

 

0.85 (0.17)

 

 Yes (N = 110)

0.63 (0.27)

 

0.66 (0.24)

 

0.74 (0.22)

 

ECOGb

 

< .0001

 

< .0001

 

< .0001

 0 (N = 117)

0.74 (0.22)

 

0.82 (0.18)

 

0.88 (0.15)

 

 1(N = 130)

0.58 (0.25)

 

0.66 (0.23)

 

0.74 (0.21)

 

MIPI

 

0.21

 

< 0.001

 

0.001

 High Risk (N = 53)

0.61 (0.27)

 

0.63 (0.28)

 

0.72 (0.26)

 

 Intermediate (N = 118)

0.66 (0.24)

 

0.75 (0.18)

 

0.82 (0.16)

 

 Low Risk (N = 79)

0.68 (0.23)

 

0.78 (0.23)

 

0.84 (0.19)

 

HgB

 

0.14

 

< 0.001

 

< 0.001

 HGB < 130 g/L (N = 137)

0.60 (0.27)

 

0.69 (0.24)

 

0.77 (0.22)

 

 HGB > =130 g/L (N = 113)

0.64 (0.20)

 

0.79 (0.19)

 

0.85 (0.16)

 

Previous lines of therapy

 

0.43

 

0.35

 

0.35

 1 (N = 98)

0.68 (0.24)

 

0.74 (0.23)

 

0.81 (0.19)

 

 2 (N = 69)

0.64 (0.24)

 

0.75 (0.23)

 

0.82 (0.18)

 

 ≥3 (N = 83)

0.64 (0.25)

 

0.70 (0.23)

 

0.78 (0.22)

 
  1. ECOG Eastern Cooperative Oncology Group, EVS England value set, MCL Mantle cell lymphoma, MIPI Mantle Cell Lymphoma International Prognostic Index, HgB haemoglobin
  2. aLymphoma B symptoms are symptoms common in lymphomas affecting B-cells and include, among others, fever, night sweats, persistent fatigue, or itchy skin. bPatients in ECOG performance status 0 are patients considered to be fully active with no performance restriction. Patients in ECOG performance status 1 are those who are restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature